Products
Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-721
Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-721-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-721-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-721-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-721-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Afelimomab Biosimilar, Fab Fusion, Anti-Tnf Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
| INN Name | Afelimomab |
| Target | TNF |
| Format | Fab Fusion |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | F(ab')2 - G3 - kappa |
| VD LC | F(ab')2 - G3 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Abbott Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
<